NYSE:SNN - Smith & Nephew Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$35.47 +0.36 (+1.03 %)
(As of 07/22/2018 12:04 PM ET)
Previous Close$35.47
Today's Range$35.30 - $35.55
52-Week Range$33.79 - $40.43
Volume225,379 shs
Average Volume496,674 shs
Market Capitalization$15.51 billion
P/E RatioN/A
Dividend Yield1.92%
Smith & Nephew logoSmith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

Receive SNN News and Ratings via Email

Sign-up to receive the latest news and ratings for SNN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical appliances & supplies


Debt-to-Equity Ratio0.31
Current Ratio2.03
Quick Ratio1.06


Trailing P/E RatioN/A
Forward P/E Ratio18.28
P/E Growth2.75

Sales & Book Value

Annual Sales$4.77 billion
Price / Sales3.26
Cash Flow$2.9098 per share
Price / Cash12.19
Book Value$10.61 per share
Price / Book3.34


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares437,360,000
Market Cap$15,513.09

Smith & Nephew (NYSE:SNN) Frequently Asked Questions

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew declared a None dividend on Wednesday, February 14th. Stockholders of record on Friday, April 6th will be given a dividend of $0.444 per share on Wednesday, May 9th. The ex-dividend date of this dividend is Thursday, April 5th. View Smith & Nephew's Dividend History.

How were Smith & Nephew's earnings last quarter?

Smith & Nephew plc (NYSE:SNN) released its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.59. View Smith & Nephew's Earnings History.

What price target have analysts set for SNN?

6 equities research analysts have issued 1 year target prices for Smith & Nephew's stock. Their forecasts range from $45.00 to $45.00. On average, they anticipate Smith & Nephew's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price. View Analyst Ratings for Smith & Nephew.

What is the consensus analysts' recommendation for Smith & Nephew?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Smith & Nephew stock?

Here are some recent quotes from research analysts about Smith & Nephew stock:
  • 1. According to Zacks Investment Research, "Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world " (7/20/2018)
  • 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $45 PT following Q4/17 sales results. Sales in the quarter were supported by strong global knee sales driven by above- market growth of Journey II in the US and Anthem in emerging markets. In recon we also highlight encouraging early momentum for Navio with management noting a ~50% increase in system sales, 500 surgeons trained in the US, and Navio accounts showing 2x growth in knees. While still early (2017 was the first full year of TKA launch) strong momentum in knees/Navio is encouraging given knees represent ~20% of overall revenue mix on a historical basis. Guidance came in a bit light relative to expectations — something we view as a conservative move given the pending CEO change. In sum, we reiterate our thesis that SNN is positioned to surprise investors in 2018 with a product portfolio capable of delivering accelerating growth and upside to profitability metrics." (2/8/2018)

Are investors shorting Smith & Nephew?

Smith & Nephew saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 2,115,136 shares, an increase of 95.6% from the June 15th total of 1,081,523 shares. Based on an average daily volume of 722,104 shares, the short-interest ratio is presently 2.9 days. View Smith & Nephew's Current Options Chain.

Who are some of Smith & Nephew's key competitors?

Who are Smith & Nephew's key executives?

Smith & Nephew's management team includes the folowing people:
  • Mr. Graham Timothy Baker, CFO & Exec. Director (Age 50)
  • Mr. Namal Nawana, CEO & Exec. Director (Age 47)
  • Mr. Matthew R. Stober, Pres of Global Operations (Age 50)
  • Mr. Arjun Rajaratnam, Chief Compliance Officer
  • Ms. Catheryn O'Rourke, Chief Legal Officer (Age 45)

Has Smith & Nephew been receiving favorable news coverage?

Headlines about SNN stock have been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Smith & Nephew earned a coverage optimism score of 0.19 on Accern's scale. They also gave news articles about the medical equipment provider an impact score of 45.16 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Smith & Nephew's major shareholders?

Smith & Nephew's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Cambiar Investors LLC (1.38%), Fisher Asset Management LLC (0.48%), Dalton Greiner Hartman Maher & Co. (0.09%), Bank of Montreal Can (0.01%), Confluence Investment Management LLC (0.00%) and Cibc Bank USA (0.00%). View Institutional Ownership Trends for Smith & Nephew.

Which major investors are selling Smith & Nephew stock?

SNN stock was sold by a variety of institutional investors in the last quarter, including Cambiar Investors LLC and World Asset Management Inc. View Insider Buying and Selling for Smith & Nephew.

Which major investors are buying Smith & Nephew stock?

SNN stock was bought by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Confluence Investment Management LLC, Bank of Montreal Can, Fisher Asset Management LLC and Cibc Bank USA. View Insider Buying and Selling for Smith & Nephew.

How do I buy shares of Smith & Nephew?

Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Smith & Nephew's stock price today?

One share of SNN stock can currently be purchased for approximately $35.47.

How big of a company is Smith & Nephew?

Smith & Nephew has a market capitalization of $15.51 billion and generates $4.77 billion in revenue each year. The medical equipment provider earns $767 million in net income (profit) each year or $1.90 on an earnings per share basis. Smith & Nephew employs 15,933 workers across the globe.

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is 15 ADAM STREET, LONDON X0, WC2N 6LA. The medical equipment provider can be reached via phone at 44-20-7401-7646 or via email at [email protected]

MarketBeat Community Rating for Smith & Nephew (NYSE SNN)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  294 (Vote Outperform)
Underperform Votes:  534 (Vote Underperform)
Total Votes:  828
MarketBeat's community ratings are surveys of what our community members think about Smith & Nephew and other stocks. Vote "Outperform" if you believe SNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.